Compare Mutual Funds
Select a Mutual Fund
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.37 | - |
NAV | ₹13.56 | - |
Fund Started | 16 Jan 2024 | - |
Fund Size | ₹508.73 Cr | - |
Exit Load | Exit load of 1%, if redeemed within 1 months. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.37
-
NAV
₹13.56
-
Fund Started
16 Jan 2024
-
Fund Size
₹508.73 Cr
-
Exit Load
Exit load of 1%, if redeemed within 1 months.
-
1 Year | 4.29% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
4.29%
-
3 Year
-
-
5 Year
-
-
Equity | 98.58% | - |
Cash | -4.95% | - |
Equity
98.58%
-
Cash
-4.95%
-
Top 10 Holdings |
| - |
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.91% |
JB Chemicals & Pharmaceuticals Ltd. | 8.38% |
Max Healthcare Institute Ltd. | 6.90% |
Laurus Labs Ltd. | 5.44% |
Fortis Healthcare Ltd. | 5.25% |
Lupin Ltd. | 4.79% |
Divi's Laboratories Ltd. | 4.50% |
Cipla Ltd. | 3.90% |
Alkem Laboratories Ltd. | 2.76% |
Neuland Laboratories Ltd. | 2.49% |
-
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | - |
Launch Date | 16 Jan 2024 | - |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
-
Launch Date
16 Jan 2024
-